Key result
Previous studies have failed to show a survival benefit of prophylactic implantation of an implantable cardioverter-defibrillator at the time of coronary artery bypass grafting or early after acute MI.
Why the study?
Does an implantable or wearable cardioverter defibrillator prevent sudden cardiac death in patients with left ventricular dysfunction after coronary artery bypass grafting?
Does an implantable or wearable cardioverter defibrillator prevent sudden cardiac death in patients with left ventricular dysfunction after coronary artery bypass grafting?
Answers are grounded in this paper and cite their sources.
This commentary discusses the clinical dilemma of preventing sudden cardiac death early after CABG in patients with left ventricular dysfunction, given that previous studies failed to show a survival benefit for prophylactic ICD implantation in this setting.
Sudden cardiac death (SCD) is a well-known complication after coronary revascularization in patients with left ventricular dysfunction. Implantable cardioverter-defibrillator (ICD) therapy is associated with a reduction in the rate of death due to life-threatening ventricular arrhythmia (VA). The SCD rate could be greatest in the early period of revascularization. However, previous studies failed to show survival benefit of prophylactic implantation of ICD at the time of coronary artery bypass grafting (CABG)1 or early after acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Takashi Murashita (2022) conducted an editorial in Left ventricular dysfunction after coronary revascularization. Implantable or wearable cardioverter defibrillator was evaluated. Previous studies have failed to show a survival benefit of prophylactic implantation of an implantable cardioverter-defibrillator at the time of coronary artery bypass grafting or early after acute MI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: